872355-52-7

Basic information

• Product Name: METHYL 6-AMINO-2-METHYLNICOTINATE
• Synonyms: METHYL 6-AMINO-2-METHYLNICOTINATE
• CAS NO: 872355-52-7
• Molecular Formula: C8H10N2O2
• Molecular Weight: 166.18
• Mol File: 872355-52-7.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 293.235°C at 760 mmHg
• Flash Point: 131.144°C
• Appearance: /
• Density: 1.195g/cm³
• Vapor Pressure: 0.002mmHg at 25°C
• Refractive Index: 1.563
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• CAS DataBase Reference: METHYL 6-AMINO-2-METHYLNICOTINATE(CAS DataBase Reference)
• NIST Chemistry Reference: METHYL 6-AMINO-2-METHYLNICOTINATE(872355-52-7)
• EPA Substance Registry System: METHYL 6-AMINO-2-METHYLNICOTINATE(872355-52-7)

Safety Data

• Hazardous Substances Data: 872355-52-7(Hazardous Substances Data)

Usage

General Description

Methyl 6-amino-2-methyl nicotinate is a complex organic compound that belongs to the class of organic compounds known as nicotinates and nicotinamides. It is derived from nicotinic acid, also known as vitamin B3. METHYL 6-AMINO-2-METHYLNICOTINATE includes a pyridine ring, which is a basic six-member ring with two nitrogen atoms. Methyl 6-amino-2-methyl nicotinate is used in various industries from pharmaceuticals to agriculture, often functioning as an intermediate compound in the synthesis of more complex chemicals. Its exact effects and safety are dependent on the final substance it forms and the context of its use. The compound is not widely discussed in a household context, rather referenced in chemical and industrial settings due to its specialized use.

InChI:InChI=1/C8H10N2O2/c1-5-6(8(11)12-2)3-4-7(9)10-5/h3-4H,1-2H3,(H2,9,10)

Upstream product

• 183428-90-2 2-amino-5-cyano-6-methylpyridine 
• 67-56-1 methanol 
• 680208-82-6 6-amino-2-methylpyridine-3-carboxylic acid? 
• 64-17-5 ethanol 
• 42753-71-9 5-bromo-6-methyl-pyridin-2-ylamine 

Downstream Products

• 1429914-08-8 ethyl 6-{[5-({(1R,2S)-2-[(tert-butoxycarbonyl)amino]cyclohexyl}amino)-2-cyanopyridin-3-yl]amino}-2-methylpyridine-3-carboxylate 
• 1429914-07-7 methyl 6-{[5-({(1R,2S)-2-[(tert-butoxycarbonyl)amino]cyclohexyl}amino)-2-cyanopyridin-3-yl]amino}-2-methylpyridine-3-carboxylate 
• 872355-54-9 6-methyl-1H-pyrrolo[2,3-b]pyridine-5-carboxylic acid methyl ester 
• 872355-55-0 6-methyl-1H-pyrrolo[2,3-b]pyridine-5-carboxylic acid 
• 1429912-31-1 5-{[(1R,2S)-2-aminocyclohexyl]amino}-3-{[5-(dimethylcarbamoyl)-6-methylpyridin-2-yl]amino}pyridine-2-carboxamide 
• 1429914-11-3 tert-butyl {(1S,2R)-2-[(6-carbamoyl-5-{[5-(dimethylcarbamoyl)-6-methylpyridin-2-yl]amino}pyridin-3-yl)amino]cyclohexyl}carbamate 

Relevant articles and documents

Structure-based drug design of novel and highly potent pyruvate dehydrogenase kinase inhibitors

Pyruvate dehydrogenase kinases (PDHKs) are fascinating drug targets for numerous diseases, including diabetes and cancers. In this report, we describe the result of our structure-based drug design from tricyclic lead compounds that led to the discovery of highly potent PDHK2 and PDHK4 dual inhibitors in enzymatic assay. The C3-position of the tricyclic core was explored, and the PDHK2 X-ray structure with a representative compound revealed a novel ATP lid conformation in which the phenyl ring of Phe326 mediated the interaction of the Arg258 sidechain and the compound. Compounds with amide linkers were designed to release the ATP lid by forming an intramolecular pi-pi interaction, and these compounds showed single-digit nM IC50 values in an enzymatic assay. We also explored the C4-position of the tricyclic core to reproduce the interaction observed with the C3-position substitution, and the pyrrolidine compound showed the same level of IC50 values. By optimizing an interaction with the Asn255 sidechain through a docking simulation, compounds with 2-carboxy pyrrole moiety also showed single-digit nM IC50 values without having a cation-pi interaction with the Arg258 sidechain.

NOVEL AMIDE DERIVATIVE AND USE THEREOF AS MEDICINE

Provided are a novel low-molecular-weight compound that suppresses production of induction type MMPs, particularly MMP-9, rather than production of hemostatic type MMP-2, as well as a prophylactic/therapeutic drug for autoimmune diseases or osteoarthritis. An amide derivative represented by the following formula (I) wherein each symbol is as defined in the specification, or a pharmacologically acceptable salt thereof.